Drug Type Antibody-cell Conjugate (ACC) |
Synonyms Anti-CD3 x Anti-EGFR Bispecific Antibody Armed T Cells(University of Virginia) |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic carcinoma non-resectable | Phase 2 | US | 06 Nov 2024 |